Innate Pharma (NASDAQ:IPHA) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reiterated their buy rating on shares of Innate Pharma (NASDAQ:IPHA – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $11.50 target price on the stock. Innate Pharma Stock Down 0.9 % Shares of Innate Pharma stock opened at $2.35 on Wednesday. Innate […]
More Stories
Solidus Ai Tech (AITECH) Achieves Self Reported Market Capitalization of $90.06 Million
Solidus Ai Tech (AITECH) traded up 5.6% against the dollar during the one day period ending at 0:00 AM Eastern...
Stellar (XLM) Price Hits $0.0905 on Top Exchanges
Stellar (XLM) traded up 1.5% against the dollar during the 1-day period ending at 0:00 AM Eastern on June 24th....
Fellaz (FLZ) Price Reaches $2.63 on Major Exchanges
Fellaz (FLZ) traded up 4.7% against the dollar during the one day period ending at 0:00 AM E.T. on June...
ConstitutionDAO Trading Up 4.9% This Week (PEOPLE)
ConstitutionDAO (PEOPLE) traded up 6.8% against the dollar during the twenty-four hour period ending at 0:00 AM Eastern on June...
Lisk (LSK) Trading 3.2% Higher This Week
Lisk (LSK) traded 3.7% higher against the US dollar during the 24-hour period ending at 0:00 AM E.T. on June...
Navalign LLC Reduces Stock Position in Meta Platforms, Inc. (NASDAQ:META)
Navalign LLC lessened its position in shares of Meta Platforms, Inc. (NASDAQ:META – Free Report) by 9.1% during the 1st...